The Administrative Core will provide for the administration of the Lymphoma SPORE, including administrative and budget support for all SPORE investigators. The Administrative Core directly supports management of SPORE projects, cores, and funds. Core A leverages existing institutional resources and infrastructure such as research regulatory committees, clinical trial data collection and management, clinical trial budgeting, IND development, technology licensing, and grants management. The Core will coordinate 1) monthly SPORE meetings and seminars, 2) quarterly research meetings, lectures, and symposia, 3) the annual SPORE retreat, 4) meetings of the Executive Committee and the Internal and External Advisory Boards, and 5) participation in NCI-sponsored SPORE meetings. This Core is involved with preparing and submitting annual progress reports and making decisions regarding the selection and support of the best and most promising projects. Integration and communication between the SPORE, the Department of Hematology and Hematopoietic Stem Cell Transplantation, and the Cancer Center Support (Core) Grant will be promoted. Importantly, the Administrative Core will be responsible for the oversight of the Developmental Research and Career Development Programs in the Lymphoma SPORE. Finally, the Core will also promote patient interests and equitable access to treatment on SPORE studies by working with a patient advocate to ensure that SPORE clinical studies are patient-centered, and by facilitating recruitment of minorities and underserved populations to SPORE clinical studies. Through performance of these objectives, the Administrative Core will ensure smooth functioning of the SPORE to maximize our efficiency, conserve resources, and expedite scientific progress and achievement.

Public Health Relevance

The Administrative Core is responsible for the administrative and budget support for all SPORE investigators. This Core coordinates meetings and facilitates the selection and support of the most promising projects. Therefore, it is ensured that resources are best spent towards developing new breakthroughs that may benefit patients in need of novel treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Mei, Matthew G; Cao, Thai M; Chen, Lu et al. (2017) Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant 23:1861-1869
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31

Showing the most recent 10 out of 97 publications